Zynerba Pharmaceuticals, Inc. (ZYNE) Investment Research Dashboard
About Zynerba Pharmaceuticals, Inc. (ZYNE) stock analysis
Get live ZYNE stock price $1.30, comprehensive Zynerba Pharmaceuticals, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ZYNE stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encount...
Company Information
- CEO
- Armando Anido MBA
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 25
Contact Information
- Website
- https://www.zynerba.com
- Address
- 80 West Lancaster Avenue
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Zynerba Pharmaceuticals, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Zynerba Pharmaceuticals, Inc.
- ⚠Investors should consider how Zynerba Pharmaceuticals, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
70.12M
P/E Ratio (TTM)
-1.65
Beta
1.19
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare ZYNE with peer companies:
- Price
- $1.29+0.00% (1D)
- Market cap
- 64.44M
- Price
- $1.04-6.31% (1D)
- Market cap
- 5.71M
- Price
- $1.91+0.00% (1D)
- Market cap
- 59.31M
- Price
- $1.36-5.56% (1D)
- Market cap
- 63.53M
- Price
- $1.27+0.00% (1D)
- Market cap
- 77.50M
- Price
- $9.40+0.53% (1D)
- Market cap
- 215.17M
- Price
- $19.37+8.52% (1D)
- Market cap
- 5.39M
- Price
- $1.07+0.00% (1D)
- Market cap
- 65.08M
- Price
- $0.76+0.00% (1D)
- Market cap
- 61.46M
- Price
- $0.10+0.00% (1D)
- Market cap
- 95.35M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
78/100 ⭐⭐⭐⭐⭐
- Overall
- +0.7%
- NYSE
- +0.6%
- NASDAQ
- +0.7%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +2.2% | +3.1% | +4.3% | 19.3 | 98/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.7% | +1.3% | +1.6% | 24.1 | 78/100⭐⭐⭐⭐⭐ |
| Communication Services | +1.4% | -0.7% | +2.9% | 22.2 | 74/100⭐⭐⭐⭐⭐ |
| Consumer Defensive | -0.2% | +1.8% | +0.7% | 29.7 | 64/100⭐⭐⭐⭐ |
| Basic Materials | +0.4% | +1.2% | -0.2% | 25.2 | 61/100⭐⭐⭐⭐ |
| Real Estate | -0.5% | +0.0% | -2.5% | 29.2 | 43/100⭐⭐⭐ |
| Energy | -2.1% | -3.7% | -4.1% | 19.1 | 39/100⭐⭐ |
| Utilities | -1.0% | +0.0% | -4.4% | 26.8 | 37/100⭐⭐ |
| Industrials | +0.6% | +0.4% | -9.9% | 30.1 | 23/100⭐ |
| Consumer Cyclical | +0.5% | -1.5% | -5.8% | 43.0 | 18/100⭐ |
| Technology | +0.6% | -1.6% | -7.2% | 40.7 | 15/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.